Differences between the modified rankin scale and barthel index in measuring intracerebral hemorrhage recovery at 12 months. (P5.051)

Abstract

Objective: The aim of this study was to examine differences in improvement of intracerebral hemorrhage (ICH) patients across commonly employed neurological assessments including the modified rankin scale (mRS) and the barthel index (BI) up to 12 months post-ICH. Background: The modified Rankin Scale (mRS) and the Barthel Index (BI) are both commonly employed measures of recovery used in intracerebral hemorrhage (ICH) patients. While these measures have been utilized routinely between 3 to 6 months post-hemorrhage, few studies have examined the utility of these measures as long-term outcome assessments. Design/Methods: 139 patients diagnosed with ICH at Yale-New Haven Hospital were prospectively enrolled between July 1, 2014 and July 1, 2016. Patients were evaluated using the mRS and BI at discharge, 3 months, 6 months, and 12 months. Repeated measures parametric and non-parametric testing were conducted to examine improvement in measures over time. Results: Using the BI, there was significant improvement across time points (p = 0.005), with follow-up testing showing improvement between discharge and 3 months (p < 0.001), 6 months (p < 0.001), and 12 months (p = 0.036), and between 3 months and 12 months (p = 0.021). There was no significant trend in mRS scores across all time points in non-parametric testing (p > 0.05). Between individual time points, there was a significant improvement in mRS scores between discharge and 3 months (p = 0.004) as well as 6 months (p = 0.010). Conclusions: These results suggest functional improvement of ICH patients in activities of daily living through 1 year post-hemorrhage. While the mRS has a plateau effect in measuring recovery for this patient population between 3 and 6 months, the BI may be a more sensitive measure for assessing recovery up to 12 months. Disclosure: Dr. Sreekrishnan has nothing to disclose. Dr. Leasure has nothing to disclose. Dr. Zhou has nothing to disclose. Dr. Greer has received personal compensation in an editorial capacity for Seminars in Neurology. Dr. Sheth has received personal compensation in an editorial capacity Current Treatment Options in Neurology. Dr. Sheth has received research support from Remedy Pharmaceuticals, Inc.